Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655278 | 0.86 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL16655156 | 0.85 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL16666121 | 0.81 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL16655244 | 0.80 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL17017431 | 0.77 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL17017439 | 0.77 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL17017449 | 0.77 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL18589264 | 0.77 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL17017434 | 0.77 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL17017446 | 0.77 | HCRTR1 (0.78) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057957-B1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-3057957-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | CNR1, GABRR1, GRIN2A | HCRTR1 72/4885HCRTR2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.